Ani Pharmaceuticals Inc. (anip 2.25 09/01/29)
13F holders, Q1 2026 (March 31)At the end of Q1 2026, 4 institutions reported holding Ani Pharmaceuticals Inc. (anip 2.25 09/01/29) in their 13F filings, unchanged from Q4 2025. 1 opened new positions and 1 sold out. The largest holders were Balyasny Asset Management L.P. ($18.6M), Boussard & Gavaudan Investment Management LLP ($16.5M) and Absolute Investment Advisers, LLC ($14.2M).
- Company
- Ani Pharmaceuticals Inc. (anip 2.25 09/01/29)
- CUSIP
- 00182CAC7
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $18.6M |
| Exits | 1 | $5.0M |
All 13F filers, Q4 2025 → Q1 2026: 15,150,000 shares bought and 4,005,150 shares sold, net +11,144,850 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Balyasny Asset Management L.P. | 0.04% | New | 15,000,000 | $18.6M |
| Boussard & Gavaudan Investment Management LLP | 3.92% | Reduce -27.8% | 13,350 | $16.5M |
| Absolute Investment Advisers, LLC | 1.67% | No change | 11,473,000 | $14.2M |
| Bank of New York Mellon Corp | 0.00% | Add +17.6% | 1,000,000 | $1.2M |
"% of holder's portfolio" is ANI PHARMACEUTICALS INC (ANIP 2.25 09/01/29)'s weight in each manager's 13F, not the share of Ani Pharmaceuticals Inc. (anip 2.25 09/01/29) the manager owns.